scholarly journals Analysis of SEC24D gene in breast cancer based on UALCAN database

2019 ◽  
Vol 14 (1) ◽  
pp. 707-711
Author(s):  
Zhi Liu ◽  
Jing Zhou ◽  
Zhibao Wang ◽  
Zhiqiang Zhou
Keyword(s):  
Breast Cancer ◽  
Survival Analysis ◽  
Cancer Patients ◽  
Literature Analysis ◽  
Breast Cancer Patients ◽  
Relapse Free Survival ◽  
Free Survival ◽  
Normal Tissues ◽  
Cancer Tissues ◽  
Lower Expression

AbstractObjectiveTo analyze the expression and its clinical significance of the SEC24D gene in breast cancer.MethodsThe dataset of breast cancer were searched in the UALCAN database, and the data obtained were mined and combined with literature analysis.ResultsThe mRNA expression of the SEC24D gene in breast cancer tissues was significantly higher than that of breast normal tissues from the UALCAN database (P < 0.05). The promoter methylation levels of the SEC24D gene in breast cancer tissues were lower than that of breast normal tissues (P < 0.05). Survival analysis showed that the relapse-free survival of breast cancer patients with a higher expression of SEC24D gene was significantly worse than those patients with a lower expression of SEC24D (P < 0.05).ConclusionThe SEC24D gene has a high expression in breast cancer tissues and its expression level was related to the prognosis of breast cancer patients.

Involvement of NK cell molecular signatures in favorable prognosis of breast cancer patients.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 10565-10565
Author(s):  
Maria Libera Ascierto ◽  
Michael O Idowu ◽  
Yingdong Zhao ◽  
Davide Bedognetti ◽  
Paolo Antonio Ascierto ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Nk Cells ◽  
Cancer Patients ◽  
Adhesion Molecules ◽  
Nk Cell ◽  
Breast Cancer Patients ◽  
Relapse Free Survival ◽  
Free Survival ◽  
Favorable Prognosis ◽  
Activating Receptors

10565 Background: Tumor cell recognition by NK cells is mediated by the interaction of activating and inhibitory NK cell receptors with their ligands expressed on tumor cells. In addition, NK cells express adhesion molecules that facilitate formation of the immunological synapse with the tumor targets. Here, we investigated whether the coordinate expression of NK activating receptors and adhesion molecules could provide a signature to segregate breast cancer patients into relapse and relapse-free outcomes. Methods: Gene expression profiling, RT-PCR screening and survival analysis were performed on RNA extracted from primary breast cancers. Tumors were obtained from patients experiencing either 5-8 years relapse-free survival or tumor relapse within 1-3 years following initial treatment. Results: Tumors from patients with a favorable prognosis were characterized by increased expression of genes involved in NK cell interaction with tumor cells and its activation signaling. In particular, up-regulation of Natural Cytotoxicity Receptors (NCRs), leukocyte function-associated antigen 1 (LFA-1), CD226 (DNAM-1) and CD96 was observed in relapse-free patients. Thus, the expression of the NK activating receptors and relevant adhesion molecules involved in NK cell:target interactions can predict relapse free survival in breast cancer patients. Conclusions: Results from the present study, highlighted the effector cooperation between the innate and adaptive immune components within the tumor microenvironment. The NK cells parameters identified in this study, together with the prognostic B and T cell signatures previously reported by us, represent a powerful tool for predicting breast cancer outcome which might be easily introduced in clinical practice.

scholarly journals The target E2F family gene PTTG1 for prediction of distant relapse-free survival in breast cancer patients receiving taxane and anthracycline-based NACT

2021 ◽  
Author(s):  
Yuhao Xu ◽  
Yaoqiang Du ◽  
Qinghui Zheng ◽  
Hongchao Tang ◽  
Yangyang Qian ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Target Genes ◽  
Cox Regression ◽  
Gene Expression Omnibus ◽  
Breast Cancer Patients ◽  
Relapse Free Survival ◽  
Free Survival ◽  
Distant Relapse ◽  
Potential Biomarker

Abstract Background Recent years, the breast cancer became the most commonly diagnosed cancer. The use of neoadjuvant chemotherapy (NACT) makes a significant contribution to chemotherapy in breast cancer. We aimed to develop the novel model as a predictor of distant relapse-free survival (DRFS) in breast cancer patients receiving taxane and anthracycline-based NACT. Methods We collected the mRNA expression datasets of patients from GSE25055 and GSE25065 in Gene Expression Omnibus (GEO). Univariate and Multivariate Cox Regression Analyses were conducted to achieve the prognostic genes that associated with DRFS. Moreover, the E2F targets genes were obtained from GSEA. We obtained the intersection genes between the prognostic genes and E2F target genes, then validated in GSE32603 dataset. And we established a nomogram model based on PTTG1 expression level and several clinical characteristics. Results A novel nomogram was conducted. The receiver operating characteristic (AUC = 0.849), C-index (0.805) and calibration plots were applied to assess the effect of this model. Conclusion Our study found that the E2F target genes, such as the PTTG1 may serve as a potential biomarker in breast cancer, and provided superior estimation of DRFS, which can guide the clinical practice in NACT of breast cancer.

Comprehensive Analysis of the Expression and Prognostic Significance of THBSs in Breast Cancer

2021 ◽  
Author(s):  
Jun Wang ◽  
Xuebing Zhan ◽  
Qian Luo ◽  
Yunshu Kuang ◽  
Xiao Liang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Expression ◽  
Protein Expression ◽  
Cancer Patients ◽  
Prognostic Value ◽  
Breast Cancer Patients ◽  
Free Survival ◽  
Expression Levels ◽  
Cancer Tissues ◽  
Mrna Expression Levels

Abstract Background: Breast cancer is one of the most common tumors for women worldwide. Thrombospondins (THBSs) are reported to play important roles in various cellular processes and are involved in the occurrence and development of human cancers. However, the expression and prognostic value of THBSs family in breast cancer remain unclear.Methods: In this study, we examined the genes and protein expression levels of THBSs and their prognostic value by synthesizing several mainstream databases, including Oncomine, Human Protein Atlas (HPA), UALCAN, and KM Plotter. We also analyzed THBS interaction networks, genetic alterations, functional enrichment, and drug sensitivity with several publicly accessible databases, including GEPIA, GeneMANIA, STRING, cBioPortal, Metascape and NCI-60 database.Results: The results showed that the mRNA expression levels of THBS1, THBS2, THBS3, and THBS5 in breast cancer tissues were significantly higher than in normal tissues. The mRNA expression levels of THBS4 were different in different subtypes of breast cancer, and the protein expression levels of THBS1, THBS2, and THBS4 in breast cancer tissues were higher than in normal breast tissues. Survival analysis showed that breast cancer patients with high THBS1 gene expression showed worse overall survival (OS), relapse-free survival (RFS), and post-progression survival (PPS), and breast cancer patients with high THBS2 gene expression also showed worse RFS. Conversely, lower THBS3 levels predicted worse RFS, and lower THBS4 levels predicted worse OS, RFS, and distant metastasis-free survival (DMFS). Conclusions: These results suggest that THBSs may be potential biomarkers for breast cancer.

scholarly journals High mutation burden of circulating cell‐free DNA in early‐stage breast cancer patients is associated with a poor relapse‐free survival

2020 ◽  
Vol 9 (16) ◽  
pp. 5922-5931
Author(s):  
Jouni Kujala ◽  
Jaana M. Hartikainen ◽  
Maria Tengström ◽  
Reijo Sironen ◽  
Veli‐Matti Kosma ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Early Stage ◽  
Early Stage Breast Cancer ◽  
Breast Cancer Patients ◽  
Relapse Free Survival ◽  
Cell Free Dna ◽  
Free Survival ◽  
Free Dna ◽  
Mutation Burden

scholarly journals Prognostic impact of the glypican family of heparan sulfate proteoglycans on the survival of breast cancer patients

2021 ◽  
Author(s):  
Paulina Karin Grillo ◽  
Balázs Győrffy ◽  
Martin Götte
Keyword(s):  
Breast Cancer ◽  
Gene Expression ◽  
Heparan Sulfate ◽  
Cancer Patients ◽  
Heparan Sulfate Proteoglycans ◽  
Prognostic Impact ◽  
Breast Cancer Patients ◽  
Relapse Free Survival ◽  
Free Survival ◽  
The Impact

Abstract Purpose Dysregulated expression of proteoglycans influences the outcome and progression of numerous cancers. Several studies have investigated the role of individual glypicans in cancer, however, the impact of the whole glypican family of heparan sulfate proteoglycans on prognosis of a large patient cohort of breast cancer patients has not yet been investigated. In the present study, our aim was to investigate the prognostic power of the glypicans in breast cancer patients. Methods We used a public database including both gene expression data and survival information for 3951 breast cancer patients to determine the prognostic value of glypicans on relapse-free survival using Cox regression analysis. Moreover, we performed quantitative Real-Time PCR to determine glypican gene expression levels in seven representative breast cancer cell lines. Results We found that high GPC3 levels were associated with a better prognosis in overall breast cancer patients. When stratified by hormone receptor status, we found that in worse prognosis subtypes low GPC1 levels correlate with a longer relapse-free survival, and in more favorable subtypes low GPC6 was associated with longer survival. Conclusion Our study concludes that glypicans could act as subtype-specific biomarkers for the prognosis of breast cancer patients and sparks hope for future research on glypicans possibly eventually providing targets for the treatment of the disease.

Sign in / Sign up

Export Citation Format

Share Document